drugset
drugset / Trial / NCT02263131

Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children

NCT02263131 ↗

Phase 3 Completed 416 enrolled Il-Yang Pharm. Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.

Timeline

Start
2013-10
Primary completion
2014-01
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IL-YANG FLU Vaccine Prefilled Syringe INJ. Vaccine 0.25 ml Intramuscular
Subject IL-YANG FLU Vaccine Prefilled Syringe INJ. Vaccine 0.5 ml Intramuscular
Comparator Influenza Virus Vaccine Vaccine 0.25 ml Intramuscular
Comparator Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.